Fate Therapeutics (FATE) Net Margin (2012 - 2026)
Fate Therapeutics (FATE) posted Net Margin of 11371.52% for Q1 2026, down 378.99% on a QoQ basis from 2374.07% in Q4 2025, and down 106599.0% year-over-year from N/an in Q1 2025.
Fate Therapeutics (FATE) Net Margin (2012 - 2026) Analysis & Trends
Fate Therapeutics' Net Margin history runs 14 years deep, the most recent figure standing at 11371.52% for Q1 2026.
- Quarterly Net Margin fell 106599.0% year-over-year to 11371.52% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4757.39% (up 261898.0% YoY) and the FY2025 annual result came in at 7894.25%, down 382201.0% from the prior year.
- Net Margin was 11371.52% for Q1 2026 at Fate Therapeutics, down from 2374.07% in the prior quarter.
- Across five years, Net Margin topped out at 154.22% in Q1 2023 and bottomed at 22578.39% in Q4 2024.
- A 5-year average of 6942.4% and a median of 4324.7% in 2025 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2023 — Net Margin tumbled 2112792 bps — and 2025, when it jumped 2020432 bps.
- Fate Therapeutics' Net Margin stood at 806.62% in 2022, then tumbled by 2619 bps to 21934.55% in 2023, then dropped by 3 bps to 22578.39% in 2024, then jumped by 89 bps to 2374.07% in 2025, then sank by 379 bps to 11371.52% in 2026.
- Business Quant data shows FATE's Net Margin at 11371.52% in Q1 2026, 2374.07% in Q4 2025, and 4324.7% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Fate Therapeutics | 302.48 Mn | 302.48 Mn | - | -11,371.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11,371.52% |
| Dec 31, 2025 | -2,374.07% |
| Sep 30, 2025 | -4,324.70% |
| Jun 30, 2025 | -2,358.00% |
| Mar 31, 2025 | -10,305.52% |
| Dec 31, 2024 | -22,578.39% |
| Sep 30, 2024 | -6,502.90% |
| Jun 30, 2024 | -2,892.88% |
| Mar 31, 2024 | -5,410.08% |
| Dec 31, 2023 | -21,934.55% |
| Sep 30, 2023 | -10,963.17% |
| Jun 30, 2023 | -13,075.67% |
| Mar 31, 2023 | -154.22% |
| Dec 31, 2022 | -806.62% |
| Sep 30, 2022 | -1,036.51% |
| Jun 30, 2022 | -1,443.03% |
| Mar 31, 2022 | -489.06% |
| Dec 31, 2021 | -1,733.46% |
| Sep 30, 2021 | -1,700.53% |
| Jun 30, 2021 | -948.84% |